This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2011 Apr;26(4):637-8.

doi: 10.1007/s00467-010-1671-2. Epub 2010 Oct 29.

Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy

Bizhen Zhu, Jianping Huang

PMID: 21046167
DOI: 10.1007/s00467-010-1671-2

Case Reports

Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy

Bizhen Zhu et al. Pediatr Nephrol. 2011 Apr.

. 2011 Apr;26(4):637-8.

doi: 10.1007/s00467-010-1671-2. Epub 2010 Oct 29.

Authors

Bizhen Zhu, Jianping Huang

PMID: 21046167
DOI: 10.1007/s00467-010-1671-2

No abstract available

PubMed Disclaimer

Similar articles

Rituximab in membranous nephropathy: is it a first-line treatment?
Appel GB. Appel GB. J Am Soc Nephrol. 2012 Aug;23(8):1280-2. doi: 10.1681/ASN.2012060602. Epub 2012 Jul 12. J Am Soc Nephrol. 2012. PMID: 22797189 No abstract available.
Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy.
Wen M, Küchle C, Sarkar O, Renders L, Heemann U, Schmaderer C. Wen M, et al. Int Urol Nephrol. 2014 Apr;46(4):847-8. doi: 10.1007/s11255-014-0673-6. Epub 2014 Mar 1. Int Urol Nephrol. 2014. PMID: 24585365 No abstract available.
Rituximab for membranous nephropathy and immune disease: less might be enough.
Ruggenenti P, Cravedi P, Remuzzi G. Ruggenenti P, et al. Nat Clin Pract Nephrol. 2009 Feb;5(2):76-7. doi: 10.1038/ncpneph1007. Epub 2008 Dec 2. Nat Clin Pract Nephrol. 2009. PMID: 19048001 Review. No abstract available.
Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
Cobo M, Hernández D, Rodriguez C, Pérez-Tamajón L. Cobo M, et al. Clin Nephrol. 2006 Jul;66(1):54-7. doi: 10.5414/cnp66054. Clin Nephrol. 2006. PMID: 16878436
Membranous nephropathy: the start of a paradigm shift.
Herrmann SM, Sethi S, Fervenza FC. Herrmann SM, et al. Curr Opin Nephrol Hypertens. 2012 Mar;21(2):203-10. doi: 10.1097/MNH.0b013e32835026ed. Curr Opin Nephrol Hypertens. 2012. PMID: 22240444 Free PMC article. Review.

See all similar articles

Cited by

The Clinical Profile and Long-Term Outcome of Children with Membranous Nephropathy, and the Evaluation of Anti-Phospholipase A2 Receptor Antibody Immunohistochemistry in Kidney Biopsy.
Deepthi RV, George S, Mathew G, Roy S, Bindra M, Rebekah G, Agarwal I. Deepthi RV, et al. Indian J Nephrol. 2023 Nov-Dec;33(6):432-439. doi: 10.4103/ijn.ijn_228_22. Epub 2023 May 3. Indian J Nephrol. 2023. PMID: 38174298 Free PMC article.
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R, Eldin KW, Beck LH Jr, Michael M. Malatesta-Muncher R, et al. Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15. Pediatr Nephrol. 2018. PMID: 29546599

References

1. Lancet. 2002 Sep 21;360(9337):923-4 - PubMed
1. J Nephrol. 2005 May-Jun;18(3):328-33 - PubMed
1. Pediatr Nephrol. 2006 Nov;21(11):1707-15 - PubMed
1. Kidney Int. 2008 Jan;73(1):117-25 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer